Nanotechnology for Treatment of Mesothelioma Fluid
Posted on Friday, April 19, 2013.

mesothelioma nanotechnologyA new article on diagnostic advances predicts some good news for mesothelioma patients and their doctors.

Mesothelioma is an aggressive malignancy that most often occurs in the membrane around the lungs (pleura) but can also arise in the abdominal wall or around the heart. It is known to be caused by exposure to asbestos, but its long latency period and vague early symptoms can make it difficult to diagnose until in its later stages. At that point, mesothelioma is also less survivable.

A pair of Spanish doctors, however, predicts that nanotechnology holds some good news for both diagnosing and treating the symptoms of mesothelioma. Nanotechnology in medicine involves the use of extremely tiny particles to deliver therapeutics and glean information at the cellular level.  The authors predict that the ability to deliver nanoparticles directly into the pleural space will be an important advance for managing one of the most common and problematic side effects of mesothelioma: pleural effusion.

Pleural effusion is a buildup of fluid around the lungs that can occur as a result of mesothelioma and other types of cancers and lung diseases. The fluid can constrict the lungs and make breathing difficult. When cells in the fluid become malignant, it can also cause the cancer to spread faster.

After searching more than four thousand research articles on malignant pleural effusion and diagnosis (more than 800 in the last 5 years), the authors made the following observations:

- Most pleural effusion in mesothelioma will still need to be diagnosed using ultrasound;
- Although some biomarkers found in pleural fluid can be helpful in diagnosing mesothelioma, they may not be enough by themselves to accurately diagnose malignant pleural effusion;
- In people with a history of asbestos exposure, biomarkers in the blood, including soluble mesothelin and fibulin, can help identify patients at risk for developing mesothelioma;
- Needle pleural biopsy can be a helpful way to diagnose mesothelioma-related pleural effusion but only if used with ultrasound or CT guidance;
- Thoracoscopy, or the use of a camera inside the chest, is preferable to needle biopsy for diagnosing pleural effusion and for treating it through a process called pleurodesis;
- Malignant pleural effusion animal models will help doctors both understand the workings of this condition and learn to treat it more effectively.

The authors of the article say mesothelioma patients in particular are “likely to benefit sooner than later” from some of these advances.


Rodriquez-Panadero, F & Romero-Romero, B, “Current and future options for the diagnosis of malignant pleural effusion”, April 4, 2013, Expert Opinions in Medical Diagnostics, Epub ahead of print.


© Surviving Mesothelioma and Cancer Monthly. All rights reserved.

DISCLAIMER: : Surviving Mesothelioma® is registered with the United States Patent and Trademark Office by Cancer Monthly, Inc. and the website is owned and managed by Cancer Monthly Inc. All of the information provided on this website or by any employee or contractor of Cancer Monthly is for informational purposes only. This website is not a substitute for professional medical advice, examination, diagnosis or treatment. This website should not be used for diagnosing or treating a health problem or disease and it is not a substitute for professional care. You should always seek the advice of your physician or other qualified health professional before starting any new treatment or making any changes to an existing treatment. You should not delay in seeking or disregard medical advice based on information on this website or by any employee or contractor of Cancer Monthly.